Pape, Marieke
Vissers, Pauline A. J.
Slingerland, Marije
Haj Mohammad, Nadia
van Rossum, Peter S. N.
Verhoeven, Rob H. A.
van Laarhoven, Hanneke W. M.
,
Article History
Received: 6 March 2023
Accepted: 21 July 2023
First Online: 14 August 2023
Declarations
:
: All patients provided written informed consent for participation in POCOP and linkage with the NCR. According to the Central Committee on Research involving Human Subjects, this type of study does not require approval from an ethics committee in The Netherlands. The study was approved by the Privacy Review Board of the NCR and the scientific committee of the Dutch Upper GI Cancer Group.
: NHM reports personal fees (consultancy) from BMS, Eli Lilly, Astra Zeneca, Servier, and MSD. RV has served as a consultant for Daiichi Sankyo and reports a grant from BMS. HvL reports grants or advisory/speaker role from Astellas, BMS, Daiichy, Dragonfly, Lilly, Merck, Novartis, Nordic Pharma, and Servier; research funding or medical supply from Bayer, BMS, Celgene, Janssen, Incyte, Lilly, Merck, Nordic Pharma, Philips, Roche, and Servier; and has received unrestricted research funding (non-commercial) from Dutch Cancer Society, NWO/ZonMw, European Research Council, and MaagLeverDarm Stichting. MS served as a consultant for BMS and Eli Lilly. MP, PvR, and MH have no disclosures to declare.